Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Factors associated with rituximab response in the combination cohort (cohorts 1 and 2)

From: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

Characteristics EULAR non-responders (n = 47) EULAR responders (n = 138) Univariate OR (95% CI) p value Multivariate OR (95% CI) p value
DAS28-CRP 3.2–5.1 (Ref) 26 (40.6%) 38 (59.4%) 3.26 (1.64–6.47) 0.0007 4.10 (1.90–8.85) 0.0003
>5.1 21 (17.4%) 100 (82.6%)
RF or anti-CCP Negative (Ref) 9 (47.4%) 10 (52.6%) 3.03 (1.15–8.001) 0.025 3.27 (1.13–9.46) 0.03
Positive 38 (22.9%) 128 (77.1%)
IgG > ULN (g/L) No (Ref) 36 (33.3%) 72 (66.7%) 2.55 (1.16–5.60) 0.02 2.32 (1.01–5.33) 0.048
Yes 10 (16.4%) 51 (83.6%)
Detectable IL-33 No (Ref) 37 (30.1%) 86 (69.9%) 2.24 (1.03–4.87) 0.04 2.40(1.01–5.72) 0.047
Yes 10 (16.1%) 52 (83.9%)
  1. Values are given as n (%) of responders or non-responders with a given characteristic
  2. Rituximab response was evaluated at week 24 according to EULAR response
  3. anti-CCP anti-cyclic citrullinated peptide antibody, CI confidence interval, DAS28-CRP Disease Activity Score in 28 joints by C-reactive peptide, EULAR European League Against Rheumatism, Ig immunoglobulin, OR odds ratio, Ref referent, RF rheumatoid factor, ULN upper limit of normal (i.e., 12.7 g/L)